0.29 | 8.41%
| Price and Volume | |
|---|---|
| Recent Price | 3.45 |
| 52 Week High | 6.72 |
| 52 Week Low | 1.68 |
| Avg. Daily Vol. (Mil) | 0.20 |
| Beta (3 year) | 2.07 |
| Share Related Items | |
| Mkt Cap (Mil) | 73.15 |
| Shares Out (Mil) | 21.20 |
| Float (Mil) | 20.45 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.70 |
| Current Ratio | 1.70 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 292.61 |
| Price/Book | 5.07 |
| Price/Cash Flow | -4.00 |
| Per Share Data | |
| Earnings | -0.91 |
| Sales | 0.01 |
| Book Value | 0.68 |
| Cash Flow | -0.86 |
| Business Summary | |
|---|---|
| CytRx Corporation is a biopharmaceutical research and development company, which is engaged in the development of human therapeutics. | |
| General Information | |
| 11726 San Vicente Boulevard
Suite 650 Los Angeles, CA 90049 |
|
| www.cytrx.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 15 | |
| CEO: Steven A. Kriegsman | |
| Short Interest | |
| Current Month (Mil) | 3.64 |
| Previous Month (Mil) | 2.66 |
| Short Interest Ratio (Days) | 21.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -54.80 |
| Return on Investments | -126.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,524.42 | 1,326.72 | 2,855.25 | 17.17 |
Oil *
106.70
|
|
UP
69.59 |
UP
8.90 |
UP
17.72 |
DOWN
0.28 |
10 Yr
1.72%
SPDR Gold
150.71
|
|
+0.56%
|
+0.68%
|
+0.62%
|
-1.60%
|
Data delayed 20 minutes |
Connect with TheStreet